What it is
Cagrilintide is a long-acting amylin analog studied for appetite suppression and weight management.
Evidence boundary
Human trial data exists.
Trial evidence
- PMID 42452898 — Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials.
- PMID 42009015 — Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
- PMID 41759565 — CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment.
- PMID 42207966 — Comparative Effectiveness of CagriSegma, Semaglutide, Cagrilintide and Tirzepatide in the Management of Overweight and Obesity: A Network Meta-Analysis of Randomized Clinical Trials.
- PMID 42744908 — Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 | 600 mcg | 12 U (0.12 mL) | Once weekly | 600 mcg/week |
| Weeks 3–4 | 1.2 mg | 24 U (0.24 mL) | Once weekly | 1.2 mg/week |
| Weeks 5–6 | 2.4 mg | 48 U (0.48 mL) | Once weekly | 2.4 mg/week |
| Weeks 7+ | 4.5 mg | 90 U (0.9 mL) | Once weekly | 4.5 mg/week |
Weeks 1–2
- Dose
- 600 mcg
- Draw / measure
- 12 U (0.12 mL)
- Frequency
- Once weekly
- Weekly total
- 600 mcg/week
Weeks 3–4
- Dose
- 1.2 mg
- Draw / measure
- 24 U (0.24 mL)
- Frequency
- Once weekly
- Weekly total
- 1.2 mg/week
Weeks 5–6
- Dose
- 2.4 mg
- Draw / measure
- 48 U (0.48 mL)
- Frequency
- Once weekly
- Weekly total
- 2.4 mg/week
Weeks 7+
- Dose
- 4.5 mg
- Draw / measure
- 90 U (0.9 mL)
- Frequency
- Once weekly
- Weekly total
- 4.5 mg/week
Weekly totals apply only during the active phase.
Titration rules
- 0.6 mg weekly is the cautious start.
- 1.2 mg weekly is the next step.
- 2.4 mg weekly is the middle step.
- 4.5 mg weekly is the higher step.
- Hold each step for 2 weeks before moving on.
Cycle length and breaks
Reassess before extending.
What to monitor
- Appetite reduction
- Weight-loss response
- Nausea and vomiting
- Injection-site reactions
- Do not read this as a combo-product label.
Practical rules
- Subcutaneous, once weekly.
- Rotate injection sites.
- Smaller meals and slower titration help with GI effects.
- Keep protein and resistance training in the plan if lean mass matters.
Related protocols
Semaglutide Peptide Protocol & DosingTirzepatide Peptide Protocol & DosingRetatrutide Peptide Protocol & DosingCagrilintide + Semaglutide Stack & DosingEloralintide Peptide Protocol & Dosing Supply & lot verification
Availability and batch-linked COA records for Cagrilintide Peptide Protocol & Dosing are kept with the current product listing.
View availability & COA → Verification notes